AHR and cancer: A pharmacologically optimized human kynureninase is currently moving toward clinical development for the treatment of cancers where Trp-Kyn-AhR pathway play a significant immunosuppressive role through Kyn production, and those independently of both IDO1 and TDO2 overexpression.